Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA6 | P23280 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA4 | P22748 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028599 | 1.00 | TSHR (0.46) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL27501979 | 0.90 | ALDH1A1 (0.48) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL17625007 | 0.90 | ACE2 (0.51) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL3225144 | 0.88 | TSHR (0.42) | TSHRTP53CA12CA1CA2 | |
| Toluene SCHEMBL30385005 | 0.88 | ALDH1A1 (0.47) | TSHRKDM4EPOLBGAAMAPT | |
| SCHEMBL28180523 | 0.85 | KDM4E (0.48) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL6448957 | 0.83 | KDM4E (0.47) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL3893054 | 0.83 | FOLH1 (0.43) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL928246 | 0.83 | TTR (0.47) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL2259867 | 0.82 | TSHR (0.59) | TSHRTP53CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| CN-109265443-B | Heterocyclic compounds as ASK inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | NOVARTIS AG (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3303415-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | Novartis AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-3192787-A1 | METHOD FOR PRODUCING FULLERENE DERIVATIVE | Showa Denko K.K. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC. (CH) | 2016-12-08 | — | — | US | disclosed |
| WO-2016193912-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| WO-2009060206-A1 | 3,4,6,7-TETRAHYDRO-1H-PYRROLO[3,4-D]PYRIMIDINE-2,5-DIONES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-5698580-A | TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0770609-A1 | ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT | Rational Drug Design Laboratories (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-3959351-A | INSECTICIDE, CHOLINESTERASE INHIBITOR | RESEARCH CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | SIRT5, IK, IGLV6-57 | TSHR 3033/4885TP53 1546/4885CA12 2901/4885 |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | SIRT5, IK, IGLV6-57 | TSHR 3033/4885TP53 1546/4885CA12 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.